Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 52, n° 6
pages 1082-1084 (juin 2005)
Doi : 10.1016/j.jaad.2005.03.039
BRIEF REPORTS

Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study
 

Bruce E. Strober, MD, PhD a, , Kimberly Siu, MD a, Andrew F. Alexis, MD, MPH b, Gene Kim, MD a, Ken Washenik, MD, PhD b, Animesh Sinha, MD, PhD c, Jerome L. Shupack, MD a
a From The Ronald O. Perelman Department of Dermatology, New York University School of Medicine 
b Department of Dermatology, St Luke's-Roosevelt Hospital Center 
c Department of Dermatology, Weill Medical College of Cornell University 

Correspondence to: Bruce E. Strober, MD, PhD, 560 First Ave, TCH-158, New York, NY 10016-6497.

New York, New York

Abstract

In this prospective, open-label pilot study, we evaluated the safety and efficacy of etanercept, a TNF-⍺ inhibitor, in the treatment of moderate to severe alopecia areata, alopecia totalis, or alopecia universalis. Seventeen otherwise healthy adults with moderate to severe alopecia areata were enrolled. The primary outcome measure was the extent of hair regrowth during and after the end of treatment as evaluated by the Severity of Alopecia Tool (the SALT score). After between 8 and 24 weeks of continuous treatment with etanercept 50 mg given subcutaneously twice weekly, significant regrowth of hair was not shown in any of the subjects treated. Based on these results, etanercept appears to be ineffective in treating subjects with treatment-refractory, moderate to severe alopecia areata, alopecia totalis, or alopecia universalis.

The full text of this article is available in PDF format.

 Supported in part by Amgen.
Disclosure: Drs Strober, Alexis, and Shupack have served as paid speakers and consultants for Amgen-Wyeth.
Presented as a poster at the 66th Society for Investigational Dermatology Meeting, St Louis, Missouri, May 4-7, 2005.



© 2005  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline